Ekaterina G. Deyanova

Ekaterina G. Deyanova

Auto-generated profile, based on publicly available information

Ekaterina G. Deyanova

Bristol Myers Squibb Research & Development

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
MZMengru Mira Zhang
Mengru Mira Zhang
RHRichard Huang
Richard Huang
BBBrett R. Beno
Brett R. Beno
EDEkaterina G. Deyanova
Ekaterina G. Deyanova
JLJing Li
Jing Li
MGMichael L Gross
Michael L Gross

3 September 2020 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
EDEkaterina G. Deyanova
Ekaterina G. Deyanova
RHRichard Huang
Richard Huang
PMPriyanka A. Madia
Priyanka A. Madia
PNPradyot Nandi
Pradyot Nandi
OGOlafur Gudmundsson
Olafur Gudmundsson
GCGuodong Chen
Guodong Chen

24 May 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SYSayumi Yamazoe
Sayumi Yamazoe
YPYam Poudel
Yam Poudel
ESEmanuela Sega
Emanuela Sega
AMAnandaroop Mukhopadhyay
Anandaroop Mukhopadhyay
RRRadha Ramakrishnan
Radha Ramakrishnan
ECEugene P. Chekler
Eugene P. Chekler
Herein, we describe the discovery of a novel immunostimulatory drug conjugate (IMC) that employs TLR7/8 agonists conjugated to a tumor-targeting LIV1 antibody. Targeting TLR7/8 agonists to LIV1-expressing tumors enables localized delivery, thereby minimizing systemic toxicity while promoting inflammation and T cell recruitment within the tumor microenvironment (TME) for enhanced antitumor efficacy. Dual activation of TLR7 and TLR8 within the TME facilitates the recruitment of diverse immune cells and induces a broad spectrum of pro-inflammatory cytokines, effectively reshaping the immunosuppressive TME by upregulating costimulatory molecules. The mechanism of action of the IMC involves tumor recognition via surface antigens and Fcγ-mediated phagocytosis, followed by activation of myeloid cells to efficiently present tumor antigens to T-cells, thereby eliciting antitumor immunity. The designed IMCs demonstrate the ability to activate myeloid cells in the presence of tumor cells, display robust antitumor activity, and are well tolerated in toxicology studies.